logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Febrile Neutropenia

    FiltersReset Filters
    8 results

    • cefepime

      (Cefepime)
      WG Critical Care, LLC
      Usage: Cefepime is indicated for treating moderate to severe pneumonia, febrile neutropenia, uncomplicated and complicated urinary tract infections, uncomplicated skin infections, and complicated intra-abdominal infections (with metronidazole). It should be used to target infections caused by susceptible bacteria to prevent drug resistance.

    • cefepime

      (cefepime)
      Baxter Healthcare Corporation
      Usage: Cefepime Injection is indicated for treating moderate to severe pneumonia, febrile neutropenia, uncomplicated and complicated urinary tract infections, uncomplicated skin infections, and complicated intra-abdominal infections. It should be used to combat infections caused by specific susceptible bacteria to prevent drug resistance.

    • cefepime

      (Cefepime)
      Apotex Corp.
      Usage: Cefepime for Injection is indicated for treating moderate to severe pneumonia, febrile neutropenia, uncomplicated and complicated urinary tract infections, uncomplicated skin infections, and complicated intra-abdominal infections (with metronidazole). It should be used when infections are proven or suspected to be caused by susceptible bacteria.

    • ciprofloxacin

      (ciprofloxacin)
      Sagent Pharmaceuticals
      Usage: Ciprofloxacin Injection is indicated for adult patients to treat various infections, including skin and skin structure, bone and joint, complicated intra-abdominal, nosocomial pneumonia, febrile neutropenia, inhalational anthrax, plague, chronic bacterial prostatitis, lower respiratory tract, and urinary tract infections, alongside pediatric applications for certain conditions.

    • ciprofloxacin in dextrose

      (ciprofloxacin)
      Hospira, Inc.
      Usage: Ciprofloxacin Injection is indicated for treating various infections in adults, including skin, bone and joint, complicated intra-abdominal, nosocomial pneumonia, febrile neutropenia, inhalational anthrax (post-exposure), plague, chronic bacterial prostatitis, lower respiratory tract infections, complicated urinary tract infections, and acute sinusitis.

    • neulasta

      (pegfilgrastim)
      Amgen Inc
      Usage: Neulasta is indicated to reduce the incidence of febrile neutropenia in cancer patients receiving myelosuppressive chemotherapy, and to enhance survival in patients exposed to myelosuppressive doses of radiation. It is not indicated for mobilizing peripheral blood progenitor cells for stem cell transplantation.

    • nyvepria

      (pegfilgrastim-apgf)
      Pfizer Laboratories Div Pfizer Inc
      Usage: NYVEPRIA is indicated to reduce the risk of infection, specifically febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer therapy. It is not intended for mobilizing peripheral blood progenitor cells for stem cell transplantation.

    • rolvedon

      (eflapegrastim-xnst)
      Spectrum Pharmaceuticals, Inc.
      Usage: Rolvedon is indicated to reduce the incidence of febrile neutropenia in adult patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy. It is not intended for mobilizing peripheral blood progenitor cells for stem cell transplantation.